Ardeparin

Evidence Level: L5

Predicted Indications: 6

Ardeparin

Pharmacist Assessment Report

Ardeparin: Low-molecular-weight heparin (anticoagulant) → Thrombophilia due to Protein C Deficiency, Autosomal Recessive

One-Sentence Summary

Ardeparin is a low-molecular-weight heparin anticoagulant that potentiates antithrombin III and inhibits factor Xa and thrombin. The TxGNN model predicts it may be useful for thrombophilia due to protein C deficiency, autosomal recessive, with a score of 0.9990. No clinical trials or publications were found for this indication, so the support is model prediction only.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Thrombophilia due to protein C deficiency, autosomal recessive
TxGNN Prediction Score	0.9990
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (1 of 1) – CDSCO approval status is not included in this data
Number of Listed Products	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data are not available in the data compiled for this report. Based on what is known, ardeparin is a low-molecular-weight heparin: it enhances antithrombin III activity and thereby inhibits factor Xa and thrombin.

Severe (homozygous) protein C deficiency leaves patients prone to widespread clotting, with purpura fulminans as its classic acute complication. Because ardeparin is an anticoagulant, there is a plausible link: anticoagulation is used as an adjunct alongside protein C replacement in this setting.

This link remains speculative. No trials or literature were supplied for this indication, and the high score is a model output only. Ardeparin also has limited availability in many markets, so in practice other low-molecular-weight heparins may be preferred.

India Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
130372	Lomoparin 3500IU Injection	Vial of 1 ml injection	Not recorded

Safety Considerations

Drug Interactions: 76 interactions were identified. Major-level ones among those listed include:
- Antiplatelet and anticoagulant agents: acetylsalicylic acid, clopidogrel, cilostazol, dipyridamole, abciximab, cangrelor, apixaban, betrixaban, bivalirudin, caplacizumab, antithrombin III human
- Thrombolytic: alteplase
- Others: deferasirox, ibritumomab tiuxetan, tositumomab (I-131)
Moderate-level examples include fenfluramine, sibutramine, sugammadex and radioactive iodides (I-123, I-131). The combined effect with other agents that affect clotting is mainly a higher bleeding risk.
Conditions flagged as contraindicated in the compiled data (not label text): bleeding or clotting-related conditions (e.g., hemophilia, thrombocytopenia including heparin-induced thrombocytopenia, intracranial hemorrhage, blood coagulation disease, antithrombin III deficiency, Glanzmann thrombasthenia), liver failure, active peptic ulcer disease, inflammatory bowel disease, infective endocarditis, and several retinal diseases (e.g., diabetic and hypertensive retinopathy).

Please also refer to the package insert for full safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on model output alone, with no clinical trials or publications for this indication (evidence level L5). The mechanistic link is plausible but unproven, and the drug’s bleeding risk and interactions require careful assessment.

To proceed, the following is needed:

Literature review and clinical data on low-molecular-weight heparin use in severe protein C deficiency
Detailed mechanism-of-action data
Package insert warnings and contraindications from the India label
Comparison with other, more widely available low-molecular-weight heparins
A bleeding-risk and drug-interaction management plan
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.